Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5278145

Title:Method for protecting bone marrow against chemotherapeutic drugs using transforming growth factor beta 1
Inventors:Keller, Jonathan R.; Frederick, MD, USA
Ruscetti, Francis W.; Rockville, MD, USA
Wiltrout, Robert; Frederick, MD, USA
Summary:This invention describes a method by which transforming growth factor beta one (TGF?1) may be utilized for the protection of hematopoietic stem cells from myelotoxicity due to chemotherapeutic drugs or radiation therapy. Described herein is a process for protecting hematopoietic stem cells via the administration to a subject of a therapeutically effective amount of TGF?1 24 hours prior to the administration of the chemotherapeutic drugs or radiation therapy. Further disclosed are methods by which TGF?1 is administered to the subject in an amount ranging from approximately 5 ?g to 25 ?g per kg of body weight, such that the mode of administration may be either by interfemoral arterial, interperitoneally or subcutaneously, and preferably by injection.
Abstract:The present invention relates to a method for protecting hematopoietic stem cells from the myelotoxicity of chemotherapeutic drugs or radiation therapy, which comprises, administering to a subject a therapeutically effective amount of transforming growth factor beta 1 for protecting bone marrow from the myelotoxicity of chemotherapeutic drugs or radiation therapy. The TGF.beta.1 may be administered prior (e.g. 24 hours) to the administration of the chemotherapeutic drugs or radiation therapy. Preferably, the TGF.beta.1 is administered to the subject in an amount of about 5 .mu.g to 25 .mu.g per kg body weight. The patient or subject of the present invention may be a mammal (e.g. human, domestic animal such as horse, cow, dog, cat or pig) and is preferably a human being. The mode of administration is either by interfemoral arterial, interperitoneally or subcutaneously, and preferably is by injection.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5278145
Application Number:US1992000815608
Date Filed:07/01/1992
Date Published:11/01/1994
Assignee:The USA as represented by the Department of Health and Human Services, Washington, DC, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/23/2021